Clinical trial tests herpes virus-based therapy for neurogenic bladder in people with spinal cord injury

A modified herpes virus that targets spinal cord nerve cells to treat neurogenic bladder in people with spinal cord injury is underway in a first-in-human clinical trial by UTHealth Houston at TIRR Memorial Hermann.

Liquid Biopsy May Help May Identify HPV-Associated Oropharyngeal Cancer

MONTREAL – Analysis of circulating human papillomavirus (HPV) tumor DNA and tumor DNA fragment (tumor tissue–modified viral ([TTMV])-HPV DNA using a commercially available blood test

July 11, 2023

FTC says PBMs ‘exercise vast control’ over healthcare, but stops short of calling for antitrust action

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

July 10, 2024

Peer health navigator program improves access to affirming care for transgender individuals

Transgender and gender-diverse individuals often experience additional difficulties navigating health care.

January 28, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.